Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Novavax Inc. closed 64.88% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my post earnings update for NVAX stock.

This stock price rise occurred despite broader market challenges, as the Dow Jones, S&P 500, and Nasdaq suffered notable declines, with the S&P 500 on track for its worst... Novavax (NVAX ...

The stock's fall snapped a two-day winning streak.

The street high price target from HC Wainwright & Co. is $19.0, while the street low from HC Wainwright & Co. is $19.0. Price Action: NVAX stock is up 10.4% at $8.08 at the last check Thursday.

We define profitability as GAAP operating profit, less non-cash items such as stock-based compensation and depreciation. Our expected breakeven revenue for 2027 is approximately $225 million.

NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non- qualified stock option and restricted stock units to ...

Novavax (NasdaqGS:NVAX) recently announced its earnings for Q4 2024, showing a significant improvement in net loss and loss per share, which may have positively influenced its stock price movement.